BioCentury | Feb 5, 2020
Product Development

2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent. The price -- $18.75 per share -- is a premium of...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Extra | Nov 7, 2019
Clinical News

Constellation heading for pivotal myelofibrosis trial as ASH data lifts shares

Constellation's shares nearly doubled in value Tuesday after the company reported Phase II data showing CPI-0610 plus SOC Jakavi could improve response rates for myelofibrosis patients, along with plans to launch Phase III testing of...
BC Extra | Oct 30, 2019
Company News

Oct. 29 Company Quick Takes: Incyte’s JAK inhibitor beats expectations; plus Sumitomo-Intercept, Merck KGaA-Pfizer, AMAG, Regeneron-Sanofi

Incyte surges on Jakafi sales, guidance  On the strength of 3Q19 sales of Jakafi ruxolitinib that beat estimates and resulted in an increase in full-year guidance, Incyte Corp. (NASDAQ:INCY) climbed $3.49 to $83.35 Tuesday, adding...
BC Extra | Oct 14, 2019
Clinical News

Phase III readout could position Pfizer’s JAK-1 to compete in eczema

Data from the first of two Phase III trials of Pfizer’s JAK-1 inhibitor abrocitinib to treat atopic dermatitis suggest that the oral small molecule could deliver efficacy that ranks with injectable blockbuster Dupixent dupilumab. In...
BC Extra | Aug 19, 2019
Financial News

Medicxi's returns keep flowing as Celgene's Inrebic approval delivers milestone

Friday's approval of myelofibrosis drug Inrebic fedratinib added to the windfall European venture firm Medicxi has realized from its relatively modest October 2017 investment in Impact Biomedicines Inc., likely returning more total cash than Medicxi...
BC Extra | Aug 16, 2019
Company News

Celgene’s myelofibrosis approval sets up key launch for BMS

FDA's approval of potential blockbuster Inrebic fedratinib from Celgene sets up a key launch for BMS in myelofibrosis, an indication for which only one other drug is marketed in the U.S. The agency's decision also...
BC Innovations | Jun 4, 2019
Distillery Techniques

Gemcitabine, Jevtana and Jakavi identified to treat pediatric AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified gemcitabine, Jevtana cabazitaxel and Jakavi ruxolitinib as drugs that could help treat pediatric AML. High throughput screening of a library of...
Items per page:
1 - 10 of 439